In the latest trading session, DaVita HealthCare (DVA) closed at $142.16, down 0.53% from the previous day, while the S&P 500 rose by 0.16%. Over the last month, DVA shares decreased by 0.52%, not keeping up with the Medical sector’s 2.32% gain and the S&P 500’s 3.22% increase.

Investors are eagerly anticipating DaVita HealthCare’s upcoming earnings report, with a predicted EPS of $2.47, marking an 18.75% growth from the same quarter last year. Revenue is expected to reach $3.16 billion, a 5.43% increase from the year-ago quarter. Full-year estimates show earnings of $9.62 per share and revenue of $12.74 billion.

Analyst estimates for DaVita HealthCare have recently been adjusted, reflecting short-term business trends. Positive revisions often signal a positive business outlook and can impact share price momentum. The Zacks Rank system, which currently rates DVA as a Buy (#2), considers these estimates for an operational rating system.

DaVita HealthCare, currently trading at a Forward P/E ratio of 14.85, is valued at a discount compared to its industry average of 23.18. The company’s PEG ratio of 1.09 also indicates a favorable valuation, with the Medical – Outpatient and Home Healthcare industry boasting an average PEG ratio of 1.96.

Zacks Investment Research is offering a free Special Report on profiting from the 2024 Presidential Election, highlighting 5 stocks poised to benefit regardless of the election outcome. Historical data shows that election years have been strong for the market, making these stock picks potentially lucrative during the electoral period.

Read more at Nasdaq: DaVita HealthCare (DVA) Stock Slides as Market Rises: Facts to Know Before You Trade